SemiScope Part 1. Three Korean back-end test & IP names — Neosem (253590 KQ), Exicon (092870 KQ), OpenEdge Technology (394280 KQ) — re-ranked by timeframe rather than by a single CXL-purity prism. The conclusion that the consensus comparison reaches is internally consistent but reaches it through one lens; once you swap lenses, the rank order changes for the most actionable horizon.
TL;DR
- Short-term momentum (the 2026 earnings inflection): Exicon > Neosem > OpenEdge. The consensus comp note that flags Exicon as an afterthought is reasoning purely through a CXL-purity prism. On a CLT-thesis prism — single-source DRAM low-frequency tester with Samsung’s final qualification cleared in late 2024 — Exicon is the cleanest J-curve entry of the three.
- The 2024-2025 loss / revenue-decline reset is the most under-reflected fact in the consensus comp. Neosem revenue fell 39.3% YoY in 2025 with operating margin compressed to 6.4%. Exicon ran a KRW 15.9B operating loss in 2024. OpenEdge’s 3Q YTD operating loss of KRW 21.3B is widening, not shrinking. All three are in turnaround positioning — that means volatility before the inflection.
- Long-term IP platform value (2027-2029): OpenEdge > Neosem > Exicon. Here the consensus is right. The caveat is that OpenEdge’s royalty mix at 0.4% of revenue means the J-curve inflection sits further out than the framing implies.
Bottom line — by timeframe, not by ranking:
| Name | Position type | Entry timing | Key event |
|---|---|---|---|
| Exicon | Near-term J-curve bet (CLT volume-revenue recognition) | Now | 1Q26 swing-to-profit stability, cumulative CLT install base |
| Neosem | Cycle turnaround + Gen6 / CXL 3.1 sole-source bet | After 1Q26 print | 1Q26 revenue recovery + first CXL 3.1 mass-production order |
| OpenEdge | Long-dated IP-platform option (3-5 yr) | Scaled accumulation | First LPDDR6 license disclosure + royalty mix reaches 5% |
The “Neosem = Core / OpenEdge = option / Exicon = afterthought” conclusion is coherent only under a single CXL-purity prism. Through a 2026 earnings momentum + sole-source moat prism, Exicon is the most attractive near-term name — the central re-evaluation of this report.
1. What the Consensus Comp Missed
The consensus comparison doc treats one-axis prism (CXL substitutability) as the binding constraint. Three under-weighted facts shift the picture.
1-1. Neosem (253590 KQ)
| Item | Consensus comp | SemiScope addition |
|---|---|---|
| 2025 results | Not stated explicitly | Revenue KRW 63.9B (-39.3% YoY), operating profit KRW 4.1B (-75.3% YoY), OPM 6.4% — a meaningful self-cycle slowdown |
| Advantest SSD ATE exit | Not mentioned | Advantest withdrew from SSD ATE in Jan 2025 → Gen5/Gen6 SSD Tester is effectively a sole-source structure for Neosem |
| Nov 2025 IR guidance | Not mentioned | Order momentum surged from late August. Sep-Nov bookings ran ~2x the Jan-Aug pace. Company guides to all-time-high 2026 results |
| HBM back-end entry | Not mentioned | HBM-dedicated BX burn-in tester is “under consideration” only — Techwing and Advantest have already moved. Late-mover risk |
1-2. Exicon (092870 KQ)
| Item | Consensus comp | SemiScope addition |
|---|---|---|
| 2024 results | Not mentioned | Revenue KRW 31.6B (-61.6% YoY), operating loss KRW -15.9B — starting point is a deep cyclical trough |
| CLT sole supply | Not mentioned | Samsung cleared final CLT qualification in late 2024; single supplier of LF tester from 2025 — much more concrete than the comp’s vague “Samsung partnership” framing |
| Cumulative orders (Oct 2025-Mar 2026) | Not mentioned | KRW 48.8B (CLT/Burn-in) + KRW 30.2B (SSD/CLT integrated) ≈ KRW 79B — about 2.5x of 2024 revenue, in five months of bookings |
| 2026 guidance | “Afterthought until Samsung CXL CapEx confirmed” | Company guides to first KRW 100B+ revenue year and full swing-to-profit in 2026 |
| CLT technology edge | Not mentioned | 11,520-parallel processing (vs ~500-parallel legacy), at least a 2-year technology lead vs competitors |
If you fold these in, Exicon stops being a “Samsung-CXL-dependent afterthought” and becomes “single-source CLT supplier entering its J-curve.” The consensus comp’s conclusion needs partial correction.
1-3. OpenEdge Technology (394280 KQ)
| Item | Consensus comp | SemiScope addition |
|---|---|---|
| 2024-2025 results | “Deepest moat but low CXL revenue visibility” | 2024 revenue -21.8%, operating loss KRW -24.3B (loss widened); 3Q YTD 2025 cumulative loss KRW -21.3B — the “long-dated option” framing should be read more conservatively |
| License ASP | Not mentioned | Avg ~$1.1M per deal, up sharply from prior quarter ~$0.7M — leading-node IP mix expanding |
| LPDDR6 + Samsung 4nm | Not mentioned | Core new IP under multi-customer engagement in 2025 |
| UCIe IP | “Under development” | Controller IP development complete and in validation; PHY in design start — more specific stage than the comp implies |
| Royalty revenue | “Low CXL visibility” | 1H 2025 royalty mix 0.4% (KRW 0.029B) — given the lag from license to volume, the J-curve inflection point likely sits in 2026-2027 or later |
| Break-even timing | Not mentioned | Korea Investment models BEP in 2026 vs Shinhan models +87.5% revenue growth in 2025 — the consensus dispersion is unusually wide |
2. Critical Re-Evaluation of the Consensus Comp
2-1. “OpenEdge has the deepest technology moat”
Partial agreement. The design-in switching cost on hard IP and the Memory Subsystem integration capability inside Korea is effectively monopolistic, and that part is fine. But against Synopsys and Cadence on a global comparison the gap is meaningful, and silicon-proven track record at leading nodes (N3/N2) is well behind.
“Deepest moat” should be read as “deepest moat within Korea.” OpenEdge’s moat reads less as a global multi-bagger candidate and more as a quality compounder anchored to the Korean AI/ASIC ecosystem.
2-2. “Neosem is the most genuinely irreplaceable name in CXL”
Agreed, conditionally. First-mover on CXL 1.1/2.0 plus the device-validation history with Samsung is the strongest single asset right now. But the comp under-weights the probability that CXL 3.1 introduces a dual-sourcing policy.
Implication: in a CXL 3.1 50:50 split scenario between Exicon and Neosem, Neosem’s “irreplaceability premium” gets partially diluted.
2-3. “Exicon’s Samsung relationship is strong but CXL purity and lead are weak — afterthought”
Partial agreement → active re-interpretation. The CXL-purity statement is factually correct, but this report views CLT — single-source, 11,520-parallel capacity, Samsung final-qual cleared in late 2024 — as forming a J-curve thesis independent of CXL as a Samsung DRAM back-end efficiency tool.
Through the CXL prism, Exicon is an afterthought. Through the DRAM back-end ATE prism, Exicon has the strongest near-term momentum. Both prisms are operating simultaneously, so Exicon should re-rank one tier higher than the consensus places it.
2-4. “Asymmetry: Neosem most balanced, OpenEdge long option, Exicon afterthought”
The framing collapses time horizons. Disaggregated:
- Short term (6-12 months) momentum: Exicon > Neosem > OpenEdge. Exicon’s KRW 79B cumulative bookings + KRW 100B revenue guidance is the strongest signal.
- Mid term (1-2 years) CXL cycle: Neosem > Exicon > OpenEdge. Agree with the consensus.
- Long term (3-5 years) IP platform: OpenEdge > Neosem > Exicon. Agree with the consensus.
3. Three-Name Comparison Table
3-1. Financials
| Item | Neosem | Exicon | OpenEdge |
|---|---|---|---|
| 2024 revenue (KRW B) | 105.2 | 31.6 | 15.3 |
| 2025E revenue (KRW B, prelim) | 63.9 (-39.3%) | ~60-70 (rebounding) | Wide range (Shinhan KRW 40.4B vs KI conservative) |
| 2024 OP (KRW B) | 16.5 | -15.9 | -24.3 |
| 2025E OP | 4.1 (prelim) | Swing-to-profit attempt (1H -8.6) | Sustained loss (3Q YTD -21.3) |
| 2026E guidance | “All-time-high revenue” | “KRW 100B+ revenue, swing to profit” | BEP (Korea Investment model) |
| Loss exposure | Stays profitable, but OPM compressed to 6.4% | 2024 deep loss → 2026 recovery | Chronic R&D losses → long-dated BEP |
3-2. Business & technology
| Item | Neosem | Exicon | OpenEdge |
|---|---|---|---|
| Business model | Equipment (ATE) | Equipment (ATE) | IP / EDA |
| Core sole-source position | Gen5 SSD Tester (Advantest exited) | CLT (11,520-parallel, Samsung qualified) | LPDDR5X / LPDDR6 IP (within Korea) |
| First-mover area | CXL 1.1 / 2.0 mass-production tester | CLT (LF memory tester) | NPU + Memory Subsystem integrated IP |
| Late-mover area | HBM inspection equipment | CXL segment | Leading-node (N3/N2) memory IP |
| Revenue-recognition lag | Short (6-9 months from order) | Short (6-9 months from order) | Long (license recognized immediately, royalty 2-4 years out) |
| Customer mix | Samsung, SK hynix, Micron | Samsung (dominant) | Diversified globally and in Korea |
3-3. Trend exposure summary
| Trend | Neosem | Exicon | OpenEdge |
|---|---|---|---|
| Gen6 SSD (PCIe 6.0) | Strong tailwind | Tailwind | Neutral |
| CXL 2.0 → 3.1 | Strong tailwind | Tailwind | Tailwind (indirect) |
| HBM4 / HBM4E | Neutral | Tailwind (indirect) | Neutral |
| LPDDR6 | Neutral | Neutral | Strong tailwind |
| AI-inference ASIC diversification | Tailwind | Tailwind | Strong tailwind |
| Chiplet (UCIe) | Neutral | Neutral | Tailwind → Strong |
| Automotive ADAS ASIC | Neutral | Neutral | Strong tailwind |
| Memory CapEx cycle | High beta | Highest beta | Low beta |
4. Scenario Analysis (All Three, Same Lens)
Scenario A — Memory CapEx normalizes + CXL 3.1 ramps (Bull)
- Korean memory CapEx normalizes in 2026 → back-end ATE order cycle recovers.
- Samsung CXL 3.1 line goes live; dual-sourcing policy splits Neosem and Exicon.
- Beneficiary intensity: Exicon ≥ Neosem > OpenEdge — equipment names track cycle directly; OpenEdge is lagged by IP-to-volume conversion.
Scenario B — AI inference ASIC + automotive ASIC explosion (Bull)
- Design-house diversification accelerates across AI inference and ADAS.
- LPDDR6 + UCIe adoption accelerates → OpenEdge license ASP compounds.
- Beneficiary intensity: OpenEdge > Neosem > Exicon — OpenEdge is the direct IP-diversification beneficiary; equipment names benefit only indirectly.
Scenario C — Memory CapEx recovery delayed + R&D burn accelerates (Bear)
- Samsung CapEx slows, memory pricing stays soft.
- All three stay under R&D pressure with poor revenue visibility.
- Damage intensity: Neosem > Exicon ≥ OpenEdge — Neosem most exposed to cycle recovery; OpenEdge already in loss so marginal incremental damage is bounded.
Scenario D — Global IP / ATE leaders accelerate Korea entry (Bear)
- Synopsys / Cadence expand share in Korean leading-node IP; Advantest re-enters SSD ATE.
- Damage intensity: OpenEdge > Neosem > Exicon — OpenEdge most exposed to global competition; Exicon’s CLT 11,520-parallel barrier holds the longest.
5. Action Guide for Allocators
5-1. Per-name action map
| Name | Action | Buy trigger | Sell / trim trigger |
|---|---|---|---|
| Exicon | Near-term J-curve bet / Core candidate | 1Q26 swing-to-profit stability confirmed | Signal that CLT sole-source ends (competitor entry) / Samsung DRAM CapEx slows |
| Neosem | Enter after 1Q26 print / cycle-turnaround bet | 1Q26 revenue recovers above KRW 20B + first CXL 3.1 mass-production order | HBM inspection-tool entry fails + dual-sourcing signal in Gen6 |
| OpenEdge | Scaled accumulation / option position | First LPDDR6 + Samsung 4nm license disclosed + royalty mix reaches 5% | 1H 2026 loss widens further + R&D headcount cost steps from KRW 11B → KRW 13B+ |
5-2. Where SemiScope diverges from the consensus comp
| Item | Consensus comp | SemiScope (re-rank) |
|---|---|---|
| Core #1 | Neosem | Exicon (near-term momentum) — or Neosem after 1Q26 print |
| Long option | OpenEdge | OpenEdge (agree) |
| Afterthought | Exicon | Exicon is in fact the #1 candidate on near-term momentum (re-evaluated outside the CXL prism) |
6. Final Note (Allocator’s Frame)
The consensus comp ranks the three names through a single prism — CXL substitutability — and through that prism the conclusion (Neosem = Core, OpenEdge = option, Exicon = afterthought) is internally coherent. But once you fold in the 2026 earnings data and the order-disclosure flow, the picture shifts.
- Exicon, viewed outside the CXL prism, is the strongest near-term momentum name in this trio. Single-source CLT, Samsung final-qual cleared in late 2024, KRW 79B cumulative bookings, and KRW 100B+ revenue guidance form a clean J-curve thesis. Low CXL exposure is not a weakness here — it is the strength of an independent thesis built on Samsung DRAM back-end efficiency.
- Neosem is a name where consensus has already reset once on the 2025 revenue collapse. 1Q26 is the first revenue-recovery confirmation print; before that, this remains a cycle bet. The first CXL 3.1 mass-production disclosure is the entry-confirmation signal.
- OpenEdge — agree with the consensus framing, but the 2025 widened loss and 0.4% royalty mix imply the J-curve inflection sits further out than the framing suggests. The 2026 BEP-or-not print is the watershed for the long-term valuation.
Final recommendation: Rather than collapsing the three names into a single 1-2-3 ranking, run them as time-horizon-separated bets. Exicon = short term, Neosem = mid term, OpenEdge = long-dated option. Layered exposure by timeframe delivers the best risk-adjusted setup of the available framings.
Appendix — Exicon Deep Profile
Snapshot
- Core products: CLT (Chambered Low-frequency memory Tester) at 11,520 parallel — next-gen DRAM stability tester; Gen5 SSD Tester (Samsung-supplied); Burn-in Tester; CXL 2.0 Tester; non-memory testers (SoC / CIS / DDI).
- Margins / track record: 2024 revenue KRW 31.6B / operating loss KRW -15.9B (loss-making). 1H 2025 cumulative operating loss KRW -8.6B. Cumulative new orders Oct 2025 - Mar 2026 ≈ KRW 79B (CLT / Burn-in / SSD). Both company and sell-side guide to first KRW 100B+ revenue year + full swing-to-profit in 2026.
- Technology moat: CLT 11,520-parallel processing (~20x prior-gen 500-parallel). Samsung final qualification cleared in late 2024, sole supplier of LF tester since 2025; estimated technology lead at least 2 years vs competitors.
- Investment view: Event-driven turnaround cycle name. Exited the 2024 trough via single-source CLT and large-order J-curve entry. Highest exposure to Samsung DRAM CapEx among Korean back-end ATE names.
Customer landscape
| Stage | Customer | Product / process | Status |
|---|---|---|---|
| Production | Samsung | CLT (DRAM LF tester, sole supplier) | In production. KRW 20.4B + KRW 19.6B + KRW 8.8B = KRW 48.8B total disclosed in Oct-Nov 2025 |
| Production | Samsung | CLT + SSD Tester combined supply | Additional KRW 30.2B disclosed in Mar 2026 (~95.5% of latest reported revenue) |
| Production | Samsung | Gen5 SSD Tester | In volume |
| Production | Samsung | Burn-in Tester | In volume |
| In progress | Samsung | CXL 2.0 Tester (Neosem dual-source potential) | In development + adoption push |
| In progress | Samsung | Gen6 SSD Tester | In R&D |
| In progress | Samsung S.LSI | DDI Tester, AP Tester | In development off CIS-tester base |
| Potential | SK hynix | Memory Tester | Limited share, expansion under exploration |
Quantum-jump triggers
- Trigger #1 — CLT volume cycle entry + 20+ cumulative installs. Per company guidance, hitting ~20 cumulative CLT installs at Samsung DRAM lines in 2026 supports KRW 100B+ revenue. 2024 revenue KRW 31.6B → 2026 KRW 100B+ implies ~3.2x topline + swing-to-profit.
- Trigger #2 — CXL 3.1 dual-vendor entry. If Samsung adopts a dual-sourcing policy on CXL 3.1, Exicon could capture ~50% of equipment supply alongside Neosem. CXL ASP runs ~2-3x SSD Tester levels, implying meaningful incremental revenue.
- Trigger #3 — Gen6 SSD Tester R&D → volume. R&D-line Gen6 SSD Tester supply could materialize in 2026, with volume entry in 2027. Risk: Neosem retains pole position given Advantest exit.
- Trigger #4 — Non-memory (SoC / AP / DDI) tester volume recognition. CIS-tester-derived DDI / AP testers winning a Samsung S.LSI or external fabless design-in would meaningfully de-risk the cycle dependency.
Risks & watchlist
- Single-customer concentration. Revenue is overwhelmingly Samsung-dependent — 2024’s -61.6% revenue decline is the cleanest illustration. Any Samsung CapEx slowdown flows directly into a single quarter.
- CLT competitor catch-up. No competitor is currently visible at 11,520-parallel chamber engineering, but a 2-year window is not infinite; monitor Dlight / UnTest Sci (and others) for entry signals.
- CXL 3.1 first-mover not secured. Neosem retains the lead in CXL. If Exicon stays second-source through CXL 3.1, the CXL-cycle alpha is capped.
Five checkpoints for the next 1-2 quarters
- 1Q26 print — magnitude of the swing to profit. How much of the KRW 79B order book recognizes as revenue and operating profit. The cleanest stability check.
- Cumulative CLT install count for 2026. Company guides to ~20 units. Quarterly tracking of whether installs follow the trajectory.
- CXL 3.1 Tester Samsung qualification disclosure timing. Most likely 1H 2026. Pass = dual-source seat secured. Miss = no CXL-cycle participation.
- HBM-line entry for inspection equipment. Whether HBM4E back-end-validation burden flows into CLT / Burn-in demand. A formal HBM-spec disclosure from the company would be the meaningful signal.
- Non-memory (DDI / AP) tester revenue disclosure. A separate disclosure with the line item exceeding 10% of revenue is the quantitative diversification signal.
Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.